종양학과
빈혈 관리
적혈구생성자극제(Erythropoiesis-Stimulating Agents)
Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (새로운 창 열기)
Source: Ann Oncol 2018;29(Supplement_4):iv96-110.
Indexed: PubMed 29471514
DOI: 10.1093/annonc/mdx758
High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution. (새로운 창 열기)
Source: Am J Hematol 2011;86(9):762-7.
Indexed: PubMed 21850658
DOI: 10.1002/ajh.22111
Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (새로운 창 열기)
Source: Acta Haematol 2007;117(3):162-7.
Indexed: PubMed 17148935
DOI: 10.1159/000097464
Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (새로운 창 열기)
Source: Am J Hematol 2013;88(12):990-6.
Indexed: PubMed 23873823
DOI: 10.1002/ajh.23552
Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (새로운 창 열기)
Source: J Clin Oncol 2011;29(28):3791-7.
Indexed: PubMed 21860000
DOI: 10.1200/JCO.2010.30.4899
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (새로운 창 열기)
Source: Cancer 2012;118(3):848-55.
Indexed: PubMed 21751205
DOI: 10.1002/cncr.26341
Management of anemia in cancer patients. (새로운 창 열기)
Source: Future Oncol 2011;7(4):507-17.
Indexed: PubMed 21463140
DOI: 10.2217/fon.11.24
Leczenie ostrej białaczki u Świadków Jehowy—opis przypadku i przegląd piśmiennictwa. [Treatment of acute leukemia in Jehovah's Witnesses—a case report and review of the literature.] [Polish, English abstract] (새로운 창 열기)
Source: Acta Haematol Pol 2007;38(4):479-84.
Indexed: EMBASE 2008089811
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (새로운 창 열기)
Source: Support Care Cancer 2013;21(2):485-93.
Indexed: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (새로운 창 열기)
Source: BJU Int 2011;108(10):1582-7.
Indexed: PubMed 21443653
DOI: 10.1111/j.1464-410X.2011.10173.x
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (새로운 창 열기)
Source: J Clin Oncol 2010;28(13):2239-45.
Indexed: PubMed 20368566
DOI: 10.1200/JCO.2009.25.1835
Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (새로운 창 열기)
Source: J Clin Oncol 2015;33(15):1674-9.
Indexed: PubMed 25870085
DOI: 10.1200/JCO.2014.57.9912
Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (새로운 창 열기)
Source: Br J Cancer 2011;105(9):1267-72.
Indexed: PubMed 21959870
DOI: 10.1038/bjc.2011.395
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (새로운 창 열기)
Source: J Intern Med 2017;281(3):284-99.
Indexed: PubMed 27926979
DOI: 10.1111/joim.12579
How I treat cancer-associated anemia. (새로운 창 열기)
Source: Blood 2020;136(7):801-13.
Indexed: PubMed 32556170
DOI: 10.1182/blood.2019004017
Update on safety of ESAs in cancer-induced anemia. (새로운 창 열기)
Source: J Natl Compr Canc Netw 2012;10(5):659-66.
Indexed: PubMed 22570294
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (새로운 창 열기)
Source: Eur J Haematol. 2023 110(4):354-61.
Indexed: PubMed 36480004
DOI: 10.1111/ejh.13910
A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (새로운 창 열기)
Source: Int J Hematol 2015;102(4):401-12.
Indexed: PubMed 26323997
DOI: 10.1007/s12185-015-1862-5
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (새로운 창 열기)
Source: Cancer 2013;119(1):107-14.
Indexed: PubMed 22744794
DOI: 10.1002/cncr.27686
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (새로운 창 열기)
Source: J Natl Cancer Inst 2013;105(14):1018-26.
Indexed: PubMed 23860204
DOI: 10.1093/jnci/djt145
Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (새로운 창 열기)
Source: Cancer Sci 2013;104(4):481-5.
Indexed: PubMed 23331490
DOI: 10.1111/cas.12105
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (새로운 창 열기)
Source: Br J Haematol 2019;184(2):134-60.
Indexed: PubMed 30549002
DOI: 10.1111/bjh.15707
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (새로운 창 열기)
Source: Support Care Cancer 2012;20(1):159-65.
Indexed: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (새로운 창 열기)
Source: Leuk Lymphoma. 2019;60(9):2324-7.
Indexed: PubMed 30773115
DOI: 10.1080/10428194.2019.1577414
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (새로운 창 열기)
Source: Oncologist 2010;15(9):935-43.
Indexed: PubMed 20798194
DOI: 10.1634/theoncologist.2009-0279
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (새로운 창 열기)
Source: Lung Cancer 2012;76(3):478-85.
Indexed: PubMed 22277104
DOI: 10.1016/j.lungcan.2011.12.015
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (새로운 창 열기)
Source: Eur J Haematol 2016;97(1):33-8.
Indexed: PubMed 26341961
DOI: 10.1111/ejh.12679
철분정맥주사
Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (새로운 창 열기)
Source: Ann Oncol 2018;29(Supplement_4):iv96-110.
Indexed: PubMed 29471514
DOI: 10.1093/annonc/mdx758
Intravenous iron in oncology. (새로운 창 열기)
Source: J Natl Compr Canc Netw 2008;6(6):585-92.
Indexed: PubMed 18597712
Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials. (새로운 창 열기)
Source: J Clin Med. 2022;11(14):4156.
Indexed: PubMed 35887920
DOI: 10.3390/jcm11144156
Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (새로운 창 열기)
Source: Int J Colorectal Dis 2016;31(3):543-51.
Indexed: PubMed 26694926
DOI: 10.1007/s00384-015-2461-x
How I treat cancer-associated anemia. (새로운 창 열기)
Source: Blood 2020;136(7):801-13.
Indexed: PubMed 32556170
DOI: 10.1182/blood.2019004017
Total dose iron dextran infusion in cancer patients: is it SaFe2+? (새로운 창 열기)
Source: J Natl Compr Canc Netw 2012;10(5):669-76.
Indexed: PubMed 22570295
Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. (새로운 창 열기)
Source: Am J Hematol 2012;87(3):308-10.
Indexed: PubMed 22262486
DOI: 10.1002/ajh.22262
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (새로운 창 열기)
Source: Eur J Haematol. 2023 110(4):354-61.
Indexed: PubMed 36480004
DOI: 10.1111/ejh.13910
Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (새로운 창 열기)
Source: Curr Oncol. 2023 24;30(9):7836-51.
Indexed: PubMed 37754484
DOI: 10.3390/curroncol30090569
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (새로운 창 열기)
Source: Cochrane Database Syst Rev 2016;(2):CD009624.
Indexed: PubMed 26845108
DOI: 10.1002/14651858.CD009624.pub2
Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (새로운 창 열기)
Source: World J Gastroenterol 2014;20(8):1972-85.
Indexed: PubMed 24587673
DOI: 10.3748/wjg.v20.i8.1972
Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (새로운 창 열기)
Source: South Asian J Cancer. 2023 15;12(2):93-9.
Indexed: PubMed 37969669
DOI: 10.1055/s-0043-1771445
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (새로운 창 열기)
Source: J Clin Oncol 2008;26(10):1619-25.
Indexed: PubMed 18375891
DOI: 10.1200/JCO.2007.12.2051
Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (새로운 창 열기)
Source: J Cancer Res Clin Oncol 2012;138(2):179-87.
Indexed: PubMed 21972052
DOI: 10.1007/s00432-011-1072-3
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (새로운 창 열기)
Source: Ann Oncol 2013;24(2):475-82.
Indexed: PubMed 23071262
DOI: 10.1093/annonc/mds338